Stock AnalizLivaNova PLC LIVN
Biotechnology: Electromedical & Electrotherapeutic Apparatus · data as of November 13, 2026
LivaNova PLC (LIVN) is a healthcare company listed in the US with a market value of about $5.0B. In the twelve months to September 30, 2026 it had revenue of $1.5B and net income of $196M, a net margin of 13.0%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a P/E of 26.7, a price to free cash flow of 39.0, 5-year revenue growth of 8% a year, a 5-year average ROIC of 2%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 72% below the current price.
Score: 2.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5B | $1.4B | $1.3B | $1.2B | $1.0B | $1.0B | $934M | $1.1B | $1.1B | $1.0B | $965M |
| Net income | $196M | -$242M | $63M | $18M | -$86M | -$136M | -$349M | -$158M | -$189M | -$25M | -$63M |
| Free cash flow | $129M | $173M | $136M | $40M | $43M | $77M | -$114M | -$116M | $83M | $58M | $52M |
| EPS (diluted) | $3.42 | $-4.45 | $1.16 | $0.32 | $-1.61 | $-2.68 | $-7.18 | $-3.26 | $-3.91 | $-0.52 | $-1.28 |
| Net margin | 13.0% | -17.5% | 5.0% | 1.5% | -8.4% | -13.1% | -37.3% | -14.5% | -17.1% | -2.5% | -6.5% |
| ROIC | — | 9.6% | 4.6% | -2.8% | -3.4% | -0.0% | -15.1% | -8.1% | -10.7% | 3.0% | 1.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $105.09, 15% above the current price; targets range from $75.00 to $120.00; the consensus rating is “Buy”; expected EPS is $4.43 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is LivaNova’s P/E ratio?
About 26.7, based on the last twelve months of diluted earnings per share (forward P/E about 20.8).
Is LivaNova stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 72% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does LivaNova pay a dividend?
Not currently.
Is LivaNova a good stock to buy?
We do not give buy or sell advice. LivaNova scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.